» Articles » PMID: 37370840

Metabolomics-Guided Identification of a Distinctive Hepatocellular Carcinoma Signature

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Jun 28
PMID 37370840
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatocellular carcinoma (HCC) is a major contributor to cancer-related morbidity and mortality burdens globally. Given the fundamental metabolic activity of hepatocytes within the liver, hepatocarcinogenesis is bound to be characterized by alterations in metabolite profiles as a manifestation of metabolic reprogramming.

Methods: HCC and adjacent non-tumoral liver specimens were obtained from patients after HCC resection. Global patterns in tissue metabolites were identified using non-targeted H Nuclear Magnetic Resonance (H-NMR) spectroscopy whereas specific metabolites were quantified using targeted liquid chromatography-mass spectrometry (LC/MS).

Results: Principal component analysis (PCA) within our H-NMR dataset identified a principal component (PC) one of 53.3%, along which the two sample groups were distinctively clustered. Univariate analysis of tissue specimens identified more than 150 metabolites significantly altered in HCC compared to non-tumoral liver. For LC/MS, PCA identified a PC1 of 45.2%, along which samples from HCC tissues and non-tumoral tissues were clearly separated. Supervised analysis (PLS-DA) identified decreases in tissue glutathione, succinate, glycerol-3-phosphate, alanine, malate, and AMP as the most important contributors to the metabolomic signature of HCC by LC/MS.

Conclusions: Together, H-NMR and LC/MS metabolomics have the capacity to distinguish HCC from non-tumoral liver. The characterization of such distinct profiles of metabolite abundances underscores the major metabolic alterations that result from hepatocarcinogenesis.

Citing Articles

Reprogramming of Glutamine Amino Acid Transporters Expression and Prognostic Significance in Hepatocellular Carcinoma.

Tambay V, Raymond V, Voisin L, Meloche S, Bilodeau M Int J Mol Sci. 2024; 25(14).

PMID: 39062801 PMC: 11277143. DOI: 10.3390/ijms25147558.

References
1.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

2.
Nowicki S, Gottlieb E . Oncometabolites: tailoring our genes. FEBS J. 2015; 282(15):2796-805. PMC: 4676302. DOI: 10.1111/febs.13295. View

3.
Wu D, Yang Y, Hou Y, Zhao Z, Liang N, Yuan P . Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 1. Cancer Commun (Lond). 2022; 42(1):37-55. PMC: 8753313. DOI: 10.1002/cac2.12247. View

4.
Di Gangi I, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A . Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget. 2016; 7(5):5815-29. PMC: 4868723. DOI: 10.18632/oncotarget.6808. View

5.
Cramer T, Vaupel P . Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy?. J Hepatol. 2022; 76(4):975-980. DOI: 10.1016/j.jhep.2021.12.028. View